Mesenchymal Stem Cell Derived Exosomes Repair Uterine Injury by Targeting Transforming Growth Factor-β Signaling
Huidong Liu1, Xiao Zhang1, Mengtong Zhang1
1Department of Gynecology and Obstetrics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences &Peking Union Medical College,Beijing 100005, China.
ACS Nano
|January 19, 2024
Summary
Placental mesenchymal stem cell exosomes repair uterine damage and improve fertility by reducing fibrosis. They target the TGF-β/smad pathway using specific microRNAs, offering a safe cell-free therapy for intrauterine adhesions (IUA).
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Reproductive Biology
Background:
- Intrauterine adhesions (IUA) are uterine scars causing female infertility.
- Mesenchymal stem cell (MSC)-derived exosomes show therapeutic potential for IUA.
- The precise mechanism of exosome-mediated antifibrotic effects in the endometrium is not fully understood.
Purpose of the Study:
- To investigate the therapeutic effects of placental mesenchymal stem cell (PMSC)-derived exosomes on uterine injury and fertility.
- To elucidate the molecular mechanisms underlying the antifibrotic action of PMSC-exosomes in the endometrium.
- To confirm the safety of PMSC-exosomes for intrauterine treatment.
Main Methods:
- Treatment of injured animal models with PMSC-derived exosomes.
- Assessment of uterine function, endometrial thickness, and fertility rates.
- Identification and functional analysis of key microRNAs (miRNAs) within PMSC-exosomes.
- Investigation of the TGF-β/smad signaling pathway and fibrotic markers.
Main Results:
- PMSC-exosomes restored uterine function, increased endometrial thickness, and improved fertility in injured animals.
- Three specific miRNAs (miR-125b-5p, miR-30c-5p, miR-23a-3p) were identified as key mediators.
- These miRNAs target smad2 and smad3, downregulating the TGF-β/smad pathway and reversing fibrosis.
- PMSC-exosomes demonstrated safety for intrauterine application.
Conclusions:
- PMSC-derived exosomes effectively repair endometrial damage and enhance fertility in animal models.
- The therapeutic mechanism involves the TGF-β/smad pathway regulation via specific miRNAs.
- Exosome-based cell-free therapy presents a promising strategy for treating intrauterine adhesions.
Related Concept Videos
01:19Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
01:36Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K